CTLA4 and neoplasm: In preclinical studies, ADG106 induces robust single-agent antitumor responses in multiple syngeneic tumor models and synergizes with anti-PD-(L)1 or anti-CTLA-4 checkpoint inhibitors, without showing significant toxicity (11) (22), which translated to patient studies.